Helus Pharma Inc., formerly known as Cybin Inc., is a clinical-stage pharmaceutical company based in Canada that develops novel serotonergic agonists and psychedelic-based therapeutics for mental health conditions. The company engineers proprietary synthetic molecules designed to target specific serotonin receptors, aiming to treat major depressive disorder and generalized anxiety disorder. Its lead clinical programs include HLP003, a deuterated psilocin analog in Phase 3 development for major depressive disorder, and HLP004, a deuterated dimethyltryptamine (DMT) molecule in Phase 2 trials for generalized anxiety disorder. Operating across North America and Europe, Helus Pharma focuses on creating treatments with improved pharmacokinetic profiles to address treatment resistance in mental healthcare.
